Ras Al Khaimah: The UAE-based pharmaceutical manufacturer Julphar (Gulf Pharmaceutical Industries), announced that it is launching two medications, Xelevia and Velmetia, for the management of Type 2 diabetes.
The announcement was made during a conference at the InterContinental Dubai Festival City.
The launch is part of Julphar’s licence, supply and co-marketing agreement signed in April 2014 with the global pharmaceutical leader, Merck Sharp and Dohme.
Speaking on the occasion, Dr Hussam Badr, marketing director at Julphar, said, “The launch of Xelevia and Velmetia is part of our continuing mission to develop Julphar diabetes portfolio, to support the health-care community in the region.”
